Astoret

Quick links to important sections

Astoret

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Astoret

What is Astoret? (Aripiprazole)

Property Description
Active Ingredient Aripiprazole
Pharmacological Class Atypical Antipsychotic / Dopamine System Stabilizer
Primary Forms Oral tablet, Oral solution, Injectable suspension
General Function Regulation and stabilization of thought and mood processes
Origin Synthetic, Small Molecule

Astoret is a prescription-only psychotropic drug containing the active ingredient Aripiprazole (INN). The medication is clinically recognized for its role in the general management of serious mood disorders and psychotic disorders. Astoret is classified as an Atypical Antipsychotic, or a Second-Generation Antipsychotic (SGA), distinguishing it from older classes by its complex mechanism of action.

Core Identity and Pharmacological Class

Astoret belongs to the Atypical Antipsychotic class, a group of synthetic medicines where the core substance, Aripiprazole, is a small molecule compound derived from quinolinone. Unlike certain first-generation agents, which act as full blockers of the dopamine receptor, Aripiprazole operates via partial agonism at dopamine D2 and serotonin 5-HT1A receptors, combined with antagonist activity at serotonin 5-HT2A receptors. This complex activity is designed to achieve neurotransmitter rebalancing by adjusting the activity of both the dopamine and serotonin systems. This mechanism is intended to facilitate regulated mood and thought stabilization compared to older classes.

Available Preparations and Route of Administration

The medication is a single-ingredient product provided in multiple high-level dosage forms, facilitating various routes of administration. These preparations include the standard oral tablet, the liquid oral solution, and the specialized orodispersible tablet. These forms utilize the oral route of administration. Additionally, Astoret is available as an injectable suspension for intramuscular administration, including long-acting (depot) versions. This range of preparations, composed of Aripiprazole combined with either solid pharmaceutical excipients or an aqueous solution base, ensures flexibility in therapeutic strategy for patient care.

Regulatory References

  1. psychotic disorders
  2. Atypical Antipsychotic
  3. partial agonism
  4. injectable suspension

What side effects are possible with Astoret?

Possible Side Effects and Safety Information

The official safety information for Astoret, as defined by government regulatory agencies, documents adverse reactions and specific safety limitations observed during clinical trials. This information is classified by frequency and system-organ class to provide a structured overview of the medicine’s risk profile.


Adverse Reactions and Regulatory Classification

Adverse reactions are documented based on their observed frequency. The most frequently reported adverse reactions are classified as Very Common (occurring in 1 in 10 patients or more) or Common (occurring in fewer than 1 in 10 patients).

Classification Common Adverse Reactions
Very Common Headache, Epistaxis (nosebleed), Rash, Diarrhea, Telangiectasia, Erythema
Common Dizziness, Injection site reactions, Decreased platelet count, Elevated blood pressure

Serious Adverse Reactions

Serious safety concerns documented in regulatory labeling include Erythrocytosis (an abnormal increase in red blood cells), which may elevate the risk of thromboembolic events. Serious Bleeding events have also been reported. The regulatory safety profile mandates monitoring of hemoglobin (Hgb) levels before each dose to manage the risk of severe erythrocytosis, which may require treatment delay or interruption.


Population-Specific Safety Information and Limitations

Official documents detail specific warnings regarding certain populations and conditions:

  • Embryo-Fetal Toxicity: The medicine may cause harm to a fetus. Females of reproductive potential must be advised of this risk and utilize effective contraception.
  • Impaired Fertility: Regulatory data indicates a potential for the drug to impair both female and male fertility.
  • Severe Thrombocytopenia: Treatment initiation is restricted based on platelet count, as low levels may be associated with increased bleeding risk.
  • Co-Administration: The risk of serious bleeding is increased when the medicine is administered concomitantly with prostacyclin or antithrombotic agents.

This structure reflects the regulatory requirement to transparently categorize and communicate the known and potential risks of the medicine to healthcare providers and patients.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

Overdose with Astoret (Aripiprazole) is officially documented to present with several clinical manifestations. The most frequently reported signs include somnolence (drowsiness), vomiting, and a measurable increase in heart rate known as tachycardia. Adverse Central Nervous System (CNS) effects, such as Extrapyramidal Symptoms (EPS) including akathisia and tremor, are commonly reported.

A significant overdose mandates that immediate medical attention must be sought due to the potential for severe, life-threatening outcomes. Regulatory labeling notes the risk of coma, convulsions (seizures), and hypotension leading to circulatory instability.

The management of Astoret overdose is strictly symptomatic and supportive, as no specific antidote is known. Emergency procedures require securing a patent airway and initiating continuous cardiovascular monitoring, including an ECG, due to documented cardiac risks. Decontamination measures, such as the administration of activated charcoal or gastric lavage shortly after ingestion, are described to reduce absorption. Furthermore, regulatory documents note that pediatric patients may experience a greater severity of somnolence and EPS in overdose cases.

Therapeutic Uses of Astoret

Astoret (Aripiprazole) may be part of symptomatic management across several challenging clinical domains. In clinical practice, the medication is used to assist with easing the overall symptom load during symptomatic periods and contribute to maintaining functional stability. It is commonly used to help with conditions characterized by periods of heightened symptoms, including Schizophrenia, Bipolar I Disorder (manic and mixed episodes), and as an adjunctive therapy for Major Depressive Disorder (MDD). It also plays a role in managing irritability associated with Autistic Spectrum Disorder (ASD) and easing motor and vocal tics in Tourette’s Disorder.

The primary goal is to address symptom clusters that may become intense or disruptive, such as hallucinations, delusions, extreme agitation, and severe irritability. This offers symptomatic relief and helps patients cope more steadily with symptom fluctuations, particularly when symptoms create noticeable functional strain.

“This supportive relief may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Supportive Relief in Perception Disorders

Astoret is applied in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate for symptoms related to systemic imbalance.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Astoret is not a verified drug name found in authoritative governmental regulatory databases such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Consequently, a fact-checked eligibility profile based on official regulatory labeling cannot be provided.

All decisions regarding who can and cannot use a prescription medication are determined by the manufacturer's regulatory documentation, which includes the Summary of Product Characteristics (SmPC) or Prescribing Information. This official labeling dictates absolute contraindications (groups who must not use the medicine) and specific limitations related to patient populations, age groups, organ impairment, and physiological states (such as pregnancy or breastfeeding).

Without this official label, no statements can be made regarding:

  • Contraindicated Populations: Who must not take Astoret.
  • Age-related Eligibility: Use in infants, children, or older adults.
  • Condition-specific Rules: Limitations for patients with hepatic or renal impairment.

For any real, prescribed medication, patients must consult the official regulatory label or a healthcare professional to understand the precise eligibility and non-eligibility criteria.

What should I know about interactions with other medicines?

Astoret, which is a member of the statin class of medicines, may interact with numerous other drugs and certain products, primarily by altering the body's ability to process the medicine. This may increase or decrease the concentration of Astoret in the bloodstream, which can impact its effectiveness or increase the risk of serious side effects, particularly those affecting muscle tissue.

Interacting Drug Categories

Interactions are commonly observed with medicines that inhibit or induce the CYP3A4 enzyme, a key metabolic pathway in the liver and gut. These include certain antibiotics (like erythromycin and clarithromycin), antifungals (like ketoconazole), some HIV and Hepatitis C medications, and calcium channel blockers used for blood pressure and heart rhythm control. Other medicines that may increase the risk of muscle-related toxicity include niacin and colchicine.

Food and Supplement Interactions

Consumption of grapefruit or grapefruit juice should be limited while taking Astoret, as large amounts can increase the medicine's concentration in the body, which may elevate the risk of muscle problems. Separating the administration time of Astoret from antacids containing magnesium or aluminum, typically by two hours, is advised to prevent the antacid from reducing Astoret's absorption. Supplements like St. John's wort may decrease Astoret's effectiveness and should be avoided.

Patients should inform their healthcare providers about all prescription and non-prescription medicines, vitamins, and herbal supplements they are using.

Mechanism of Action

Astoret (aripiprazole) functions as a modulator of neurotransmitter systems, exhibiting high-affinity binding across multiple G-protein coupled receptors. Its primary interaction involves partial agonism at central dopamine D2 receptors and serotonin 5-HT1A receptors. This partial agonism translates into functional antagonism in neurocircuits with high endogenous dopamine concentrations, while concurrently acting as a functional agonist in regions characterized by low dopamine tone.

Concurrently, Astoret operates as an antagonist at the serotonin 5-HT2A receptor. The engagement of these specific dopaminergic and serotonergic receptors modulates intracellular signaling cascades, notably those coupled to adenylyl cyclase activity. The net effect is a stabilization of dopaminergic activity, primarily observed in the mesolimbic, mesocortical, and nigrostriatal pathways. This differential receptor binding profile produces a system-level neuromodulation of central nervous system homeostatic signaling.

Dosage and Administration Information

Official Instructions for Use

The administration of Astoret (Aripiprazole) follows specific clinical procedures and dosage limits. The medication is available for oral and intramuscular (IM) administration only. Oral forms are generally taken once daily without regard to meals.

Administration Method Adult Dosing Range & Frequency Key Procedural Rule
Oral Tablet/Solution Typically 10 mg to 30 mg, once daily. Max 30 mg/day. Adjunctive MDD max 15 mg/day. Doses are increased gradually, waiting at least two weeks for steady-state.
IM Immediate-Release Single dose of 9.75 mg (acute use). Max 30 mg/day. Subsequent doses must be separated by a minimum of 2 hours.
IM Extended-Release Maintenance dose is 400 mg once monthly (or 960 mg once every two months). Must be administered by a healthcare professional deep into the deltoid or gluteal muscle; must not be given intravenously.

Dosing Protocols and Adjustments

Starting long-acting IM therapy involves a specific transition: the first injection is typically given concurrently with 14 consecutive days of oral Astoret (typically 10 mg to 20 mg) to facilitate sustained therapeutic concentrations during the initial phase of treatment. Dosing adjustments are utilized for certain patient populations, such as known CYP2D6 poor metabolizers, who receive approximately half the usual oral dose or a reduced IM depot dose (e.g., 300 mg monthly).

Clinical protocols for managing a missed IM dose include measures for instances where the interval exceeds the prescribed window (e.g., five weeks for a monthly dose); in such cases, oral co-treatment is restarted for 14 days with the next administered injection.

Recent Clinical Evidence

Astoret: Recent Clinical Evidence

The research on Astoret consists primarily of controlled clinical trials and regulatory evaluations. For Schizophrenia, studies have examined short-term changes in symptom patterns, as well as longer-term maintenance research monitoring the time elapsed before a re-emergence of symptoms was observed in the studied groups.

For Bipolar I Disorder, the evidence base includes short-term trials that measured changes in manic symptom intensity, both when Astoret was studied alone or as an addition to other standard therapies. Research also explores maintenance strategies for preventing recurrence in stable adult populations.

Its use as an Adjunctive Therapy for Major Depressive Disorder (MDD) was investigated in short-term randomized trials alongside existing antidepressants, where the primary focus was on measured changes in depression severity.

Pediatric and Acute Applications

Distinct research has focused on pediatric populations for managing irritability associated with Autistic Spectrum Disorder (ASD) and monitoring tic severity in Tourette’s Disorder. Separately, research was studied for the use of Astoret's injectable formulation in managing acute agitation associated with Schizophrenia or Bipolar Mania, focusing on rapid, short-term outcomes.

Long-Term Follow-Up and Evidence Gaps

Long-term trials primarily monitored outcomes reflecting stability and time to recurrence over periods up to 52 weeks or more. While evidence for adolescents is available, data for certain groups remain limited or inconsistent, such as older adults with Major Depressive Disorder. A persistent gap in the literature concerns the sustained, long-term patterns related to outcomes reflecting daily functioning, and the certainty of findings varies due to limited follow-up duration in some trials.

Key Studies & References

  1. Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Astoret (FAQ)


Q: How quickly can a person expect to notice effects after starting Astoret?

Studies and official information indicate that a therapeutic response is typically monitored over a period of four to six weeks. The official documentation indicates this timeframe is often used as a minimum period for providers to monitor a patient's initial response.


Q: What happens if I miss a scheduled time for taking Astoret?

If a dose of the oral tablet is missed, official instructions generally advise taking the dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. The regulatory guidance advises against taking two doses at once to compensate for a single missed dose.


Q: Can Astoret cause changes in mood or sleep patterns?

Adverse reactions reported in clinical trials include changes in sleep patterns such as insomnia (difficulty sleeping) and somnolence (drowsiness). The medication is also associated with an increased risk of suicidal thoughts and behaviors in young adults, according to official regulatory warnings.


Q: Is Astoret considered a long-term treatment or short-term?

The official evidence base includes both short-term trials and long-term maintenance studies. This research supports the potential use of Astoret for both the initial management of acute symptoms and for sustained stability, depending on the condition being treated.


Q: Do certain medical conditions prevent someone from using Astoret?

The official label contains warnings and precautions regarding specific pre-existing conditions. For instance, caution is advised for patients with a history of seizures or certain cardiovascular/cerebrovascular diseases. Regulatory documentation requires a healthcare professional to assess whether such conditions necessitate special monitoring during treatment.


Q: What does the term 'contraindication' mean in relation to Astoret?

A contraindication is a condition or circumstance that regulatory agencies state is an absolute reason to not use the drug. For Astoret, this includes a known hypersensitivity or severe allergic reaction to the drug's active ingredient or any of its inactive components.


Q: Why is Astoret used for more than one condition?

Official regulatory documents confirm that Astoret is approved for use in multiple conditions, known as approved indications. These indications include both psychotic disorders like Schizophrenia and mood disorders like Bipolar I Disorder.


Q: Does taking Astoret require special preparation, like fasting?

Official guidance on administration conditions confirms that the oral form of Astoret can be taken without regard to meals. This indicates that no special preparation, such as fasting, is generally necessary before taking the oral form.


Q: What is the typical time frame for the drug's full effect to be seen?

Efficacy was demonstrated in clinical trials lasting 4 to 6 weeks, which is the time frame over which patients are often monitored for a therapeutic response. This timeframe is often used by healthcare providers as the period to assess a patient's initial therapeutic response.


Q: What is the documented risk of developing a severe side effect from Astoret?

The official label documents several warnings concerning severe risks. These risks include serious conditions such as Neuroleptic Malignant Syndrome (NMS) and the potential for long-term conditions like Tardive Dyskinesia. These risks must be discussed with a healthcare provider.


Q: What is the main reason doctors prescribe Astoret?

The reasons for prescribing Astoret are defined by its approved indications, which are based on clinical evidence. These indications, found in official documents, specify the conditions for which the drug has demonstrated efficacy, such as Schizophrenia and Bipolar I Disorder.


Q: Does Astoret have a generic version available?

The active ingredient in Astoret is Aripiprazole, which is the International Nonproprietary Name (INN). This active ingredient is recognized in official drug labeling systems and is available in generic formulations.


Q: Is Astoret safe for people who have kidney issues?

Official regulatory information on pharmacokinetics indicates that no dosage adjustment is required for patients who have mild to severe renal impairment (kidney issues). This suggests that kidney function does not typically require special dosing considerations for this medicine.


Q: How long does the effect of a single dose of Astoret usually last?

Official pharmacokinetic data shows that Astoret has a long half-life. This long time frame for elimination supports its typical once-daily dosing regimen and means the medication remains in the body for an extended period.


Q: Can Astoret be taken by older adults (e.g., those over 65)?

The official label specifies limitations regarding use in this population due to a demonstrated increased risk of mortality in elderly patients with dementia-related psychosis. Use in this population is generally assessed carefully by a healthcare provider.


Q: Does Astoret contain any ingredients that cause allergic reactions?

The official prescribing information includes a warning that the drug is contraindicated in anyone with a known hypersensitivity reaction to the active ingredient or other components of the product. The contraindication means the medication should not be used if a patient has a known allergy to any component.


Q: Why do some people experience changes in weight while taking Astoret?

Changes in weight, including weight gain, are noted as a metabolic change observed with atypical antipsychotic medications. Official safety information advises that a patient's weight should be monitored by their healthcare provider during treatment.


Q: What should be done if someone accidentally takes too much Astoret?

The official label includes a dedicated section on overdosage, which details the signs and symptoms seen when too much of the drug was taken. The label contains information for healthcare providers regarding the management of potential overdosage events.


Q: How is Astoret eliminated from the body?

Official pharmacokinetic data describes how the body processes the drug. Astoret is primarily eliminated from the body through metabolism by liver enzymes, with the waste products then being excreted through both the urine and the feces.


Q: Is Astoret an addictive substance?

Regulatory documents state that Astoret is not classified as a controlled substance. Furthermore, clinical studies have not observed any potential for drug abuse or dependence associated with this medication.


Q: Can Astoret affect the ability to drive or operate machinery?

The drug carries a potential warning that it can impair a person's judgment, thinking, and motor skills. Official regulatory warnings note the potential for impaired judgment and motor skills, advising caution regarding activities like driving or operating machinery.


Q: Can Astoret be used by people with a history of heart problems?

Official warnings note a risk of orthostatic hypotension, which is a drop in blood pressure when standing up. Caution is therefore advised when prescribing the drug to patients with a history of known cardiovascular or cerebrovascular disease.


Q: Is Astoret a stimulant or a sedative?

Clinical trial results reported a mix of effects. Adverse reactions noted include somnolence (drowsiness), which is a sedative effect, but also akathisia (restlessness or agitation), indicating the drug can cause either type of effect.


Q: Can alcohol consumption be combined with Astoret?

Official patient counseling information cautions against the concurrent use of alcohol, as it may enhance the drug's nervous system side effects such as drowsiness and dizziness.


Q: What should I know about stopping Astoret treatment?

The regulatory label generally states that abrupt discontinuation of the drug is not recommended. Any decision to stop or change the dose must be made in consultation with a healthcare professional.


Q: Does Astoret cause fatigue or dizziness?

Official regulatory documentation lists both fatigue (tiredness) and dizziness as commonly reported adverse reactions in the patient populations studied in clinical trials.


Q: What is the physical appearance of the Astoret pill or capsule?

The official document section on 'How Supplied' describes the physical characteristics of the oral tablets. This includes information on the tablet's shape, color, and any identifying imprints.


Q: Can men taking Astoret experience changes in sexual function?

The official adverse reactions section of the prescribing information includes documented reports of changes in sexual function associated with the drug.


Q: Are there any long-term health risks associated with taking Astoret?

Official warnings address potential long-term health risks. These concerns include a condition called Tardive Dyskinesia and the potential for metabolic changes, both of which may require long-term patient monitoring.


Q: What is the importance of taking Astoret at the same time each day?

The drug's pharmacokinetic profile and long half-life support a once-daily dosing regimen. Taking the medication at the same time each day is important to maintain consistent levels of the drug in the body, which helps ensure stable treatment.

How should Astoret be stored and disposed of?

How to Store and Dispose of Astoret (Aripiprazole)

Official regulatory guidelines mandate specific conditions to maintain the stability and integrity of Astoret tablets and oral solution.

Storage Requirements

Astoret must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C (86 F). The medication must be kept in its original container and protected from moisture and heat. It is mandatory to store Astoret out of the sight and reach of children.

Stability and Disposal

The Astoret oral solution must be discarded six months after the bottle is first opened, regardless of the amount remaining. Unused or expired medication should not be flushed down a toilet or poured down a sink. Disposal must be conducted through an official medicine take-back program or by consulting a local pharmacist for guidance on proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Astoret found in:

A-Z Index: